METHODS OF COMBINED THERAPY WITH APPLICATION OF MOLECULES RELATING TO PSL AND PCRV PSEUDOMONAS

摘要

1. An isolated binding molecule or antigen-binding fragment thereof that specifically binds to Pseudomonas PcrV, where the binding molecule: (a) binds to the same Pseudomonas PcrV epitope as the antibody or antigen-binding fragment thereof containing the variable region of the heavy chain ( VH) containing the amino acid sequence of SEQ ID NO: 216 and the variable region of the light chain (VL) containing the amino acid sequence of SEQ ID NO: 217; (b) competitively inhibits the binding of PcrV Pseudomonas to the antibody or its antigen-binding f agmentom containing VH-region, comprising the amino acid sequence of SEQ ID NO: 216 and VL-region, comprising the amino acid sequence of SEQ ID NO: 217; or (c) a combination of (a) and (b). 2. The binding molecule according to claim 1, comprising: (a) a heavy chain CDR1 comprising SYAMN (SEQ ID NO: 218), or a variant thereof, containing 1, 2, 3, or 4 conservative amino acid substitutions; Heavy chain CDR2 containing AITISGITAYYTDSVKG (SEQ ID NO: 219), or a variant thereof, containing 1, 2, 3 or 4 conservative amino acid substitutions; and a heavy chain CDR3 containing EEFLPGTHYYYGMDV (SEQ ID NO: 220), or a variant thereof containing 1, 2, 3 or 4 conservative amino acid substitutions; (b) a light chain CDR1 containing RASQGIRNDLG (SEQ ID NO: 221), or a variant containing 1, 2, 3 or 4 conservative amino acid substitutions; CDR2 light chain containing SASTLQS (SEQ ID NO: 222), or a variant thereof containing 1, 2, 3 or 4 conservative amino acid substitutions; and CDR3 light chain containing LQDYNYPWT (SEQ ID NO: 223), or a variant thereof, containing 1, 2, 3 or 4 conservative amino acid substitutions; or (c) a combination of (a) and (b). 3. A binding molecule according to claim 1, comprising: (a) a variable region of a heavy chain that is at least 90% identical to p